Attapulgite, Polycarbophil Excluded From OTC Antidiarrheal Final Monograph
This article was originally published in The Tan Sheet
Executive Summary
Activated attapulgite is reclassified from proposed Category I status to nonmonograph in the 1OTC Antidiarrheal Drug Products final monograph, published in the April 17 Federal Register
You may also be interested in...
Bismuth Subsalicylate Inclusion In Overindulgence TFM Urged By P&G
An FDA request for more information on a 13-year-old Procter & Gamble submission on bismuth subsalicylate could indicate the agency's interest in moving towards completion of the overindulgence monograph
Kaopectate Labeling Now Excludes Children’s Dosing, Pfizer Says
Pfizer has removed dosing instructions for children under 12 from its Kaopectate antidiarrheal products in compliance with the OTC final monograph for the product class, according to the company
No Evidence of Reye’s/Nonaspirin Salicylates Link - Procter & Gamble
Procter & Gamble will continue to support Reye's syndrome warnings for bismuth salicylates, provided that such warnings do not imply the ingredient increases risk of the disease